With this model, researchers may be able to discover antibody drugs capable of targeting a wide range of infectious diseases.

Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth ...

The global biotechnology industry market size is projected to expand from USD 483.0 billion in 2024 to USD 546.0 billion by ...

Boehringer Ingelheim and Synaffix B.V. ("Synaffix"), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of best-in-class antibody-drug ...

The market is projected to grow from $11B in 2024 to $40B by 2030, driven by both conventional bispecifics and advancements such as antibody-drug and radioligand conjugates. 2 Invenra has launched ...

The global biotechnology industry market size is projected to expand from USD 483.0 billion in 2024 to USD 546.0 billion by ...

Overview: AbCellera Biologics Inc. operates as a company focused on antibody drug discovery and development, with a market cap of approximately $841.79 million. Operations: The company's revenue ...

a TechBio that uses agentic AI to unlock complex targets for drug discovery, development ... including its de novo antibody design models, will rapidly design therapeutic candidates against ...

meticulously designed for antibody and autoantibody profiling in biomarker discovery. This powerful platform delivers key insights into immune responses to disease and identifies targetable biomarkers ...